LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Roivant Sciences Ltd

Geschlossen

BrancheGesundheitswesen

15.26 7.84

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15.26

Max

16.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

-22M

-274M

Verkäufe

-5.4M

2.2M

EPS

-0.29

Gewinnspanne

-12,622.627

Angestellte

750

EBITDA

-284K

-284M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+16.77% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.9B

9.5B

Vorheriger Eröffnungskurs

7.42

Vorheriger Schlusskurs

15.26

Nachrichtenstimmung

By Acuity

50%

50%

185 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Sept. 2025, 17:03 UTC

Wichtige Markttreiber

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. Sept. 2025, 16:49 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

GD Culture Shares Drop After Deal for Pallas Capital

16. Sept. 2025, 16:11 UTC

Wichtige Markttreiber

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. Sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. Sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. Sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. Sept. 2025, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. Sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 20:25 UTC

Ergebnisse

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. Sept. 2025, 20:24 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. Sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. Sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. Sept. 2025, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. Sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. Sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. Sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. Sept. 2025, 16:53 UTC

Ergebnisse

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. Sept. 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 16:15 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Commodities Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Energy Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. Sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer-Vergleich

Kursveränderung

Roivant Sciences Ltd Prognose

Kursziel

By TipRanks

16.77% Vorteil

12-Monats-Prognose

Durchschnitt 16.29 USD  16.77%

Hoch 19 USD

Tief 12 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Roivant Sciences Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

11 / 11.18Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

185 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat